Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 versus PANHEPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 versus PANHEPRIN.
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% vs PANHEPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin sodium binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa), thereby inhibiting coagulation.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting blood coagulation.
Initial IV bolus of 5000 units, followed by continuous IV infusion at 1300 units/hour (typically 25,000 units in 500 mL D5W at 26 mL/hour) for therapeutic anticoagulation; dose titrated to aPTT 1.5-2.5 times control.
80 units/kg IV bolus followed by 18 units/kg/hour continuous IV infusion; adjust to maintain aPTT 1.5-2.5 times control.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours (range 1–2 hours) after intravenous administration; dose-dependent: at therapeutic doses, half-life is about 1 hour; at higher doses, up to 2.5 hours. Clinical context: shorter half-life in pulmonary embolism, longer in renal impairment.
Terminal elimination half-life is dose-dependent: at standard IV doses (100 U/kg), mean t½ = 60 min (range 40–90 min); at high doses (400 U/kg), t½ increases to 150 min due to saturable clearance mechanisms. Clinical context: Short t½ necessitates continuous infusion or frequent subcutaneous dosing for sustained anticoagulation.
Renal: negligible; primarily metabolized by the liver and reticuloendothelial system; small amount excreted unchanged in urine (<5%). Biliary/fecal: minimal.
Primarily renal excretion of metabolites (desulfated heparin) with a minor biliary/fecal component. Unchanged heparin is not excreted renally; clearance occurs via saturable hepatic metabolism and reticuloendothelial system uptake. Renal excretion accounts for approximately 50% of total clearance at therapeutic doses, while biliary/fecal elimination is <10%.
Category A/B
Category C
Anticoagulant
Anticoagulant